telaprevir

(redirected from Incivek)
Also found in: Medical.
Related to Incivek: Victrelis
Translations

telaprevir

n telaprevir m
References in periodicals archive ?
In 2012, Incivek sales began to slip simply on rumors of a better drug.
The previous record for a drug reaching blockbuster status was set in 2011, when hepatitis C therapy Incivek from Vertex Pharmaceuticals raked in $1.
Burman's said it started developing the original version of HealthTrac in December 2009 anticipating the FDA's approval of the first protease inhibitors, a class of antivirals, to treat HCV, Incivek and Victrelis.
Research shows that adding the two new drugs -- Vertex Pharmaceuticals' Incivek and Merck & Co.
7%, with the launch of Incivek and Victrelis in 2011 boosting positive growth.
Since the preparation of this manuscript, Incivek [Telaprevir] and Victrelis [Boceprevir] have become available on the market for the treatment of Hepatitis C Genotype 1 as triple therapy using one of them in addition to ribavirin and pigulated interferon.
The studies of ALS-2200 and ALS-2158 unveiled on Friday are designed to generate data that may provide the opportunity to rapidly advance into Phase II development where the companies could evaluate a number of nucleotide-based regimens beginning in the second half of next year, including regimens with INCIVEK or VX-222, said Dr Peter Mueller, executive VP Global Research and Development, and chief scientific officer at Vertex.
Food and Drug Administration (FDA) in May 2011 and will be marketed by Vertex Pharmaceuticals under the brand name INCIVEK.
The deal, however, remains contingent on Vertex gaining necessary approvals for Incivek, a hepatitis C drug.
Cambridge, MA, announced the FDA has approved Incivek tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis.
s (NASDAQ: VRTX) Incivek (telaprevir) to treat hepatitis C is likely to be approved on or around May 23.